Skip to main content

Table 1 Patients' baseline characteristics: XELOX and FOLFOX4 groups

From: Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement

   XELOX
(n = 30)
FOLFOX4
(n = 30)
Statistical significance
p-value
Male, %   57 57  
Chinese ethnicity, %   94 100  
Mean age, years   63.9 61.9 0.936*
Mean weight, kg   61.6 59.8 0.544*
Mean height, cm   165.4 162.6 0.281*
Mean body surface area, m2   1.65 1.62 0.555*
ECOG PS, % of patients 0 34 30 0.860
  1 53 53  
  2 4 4  
Alkaline phosphatase, % abnormal   20 17 0.741
No. of metastatic sites, % of patients 1 57 53 0.822
  2 33 37  
  ≥3 10 10  
Liver metastases present, % of patients   77 50 0.034
Status at August 2009, % surviving   67 47 0.121
  1. * T-test, Kruskal-Wallis rank test.